Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Lirafugratinib→

Lirafugratinib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2549174-42-5
Molecular formula
C28H24FN7O2
Molecular weight
509.54 g/mol
Drug class
Selective fibroblast growth factor receptor (FGFR) kinase inhibitortargeted antineoplastic agent
Mechanism of action
Lirafugratinib is an oral, selective FGFR inhibitor that targets FGFR2 alterations driving tumour growth. It inhibits FGFR2 kinase signalling, reducing downstream pathway activation in FGFR2 fusion- or rearrangement-positive cholangiocarcinoma. The product label describes it as a kinase inhibitor.
Indications / reported uses
  • Treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harbouring an FGFR2 gene fusion or other rearrangement, under the US LYRFIGTU product label (approved September 23, 2026).

Sources: https://www.fda.gov/drugs/cancer-approvals/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic · https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220425Orig1s000lbl.pdf

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Selective fibroblast growth factor receptor (FGFR) kinase inhibitor; targeted antineoplastic agent

Mechanism of action

Lirafugratinib is an oral, selective FGFR inhibitor that targets FGFR2 alterations driving tumour growth. It inhibits FGFR2 kinase signalling, reducing downstream pathway activation in FGFR2 fusion- or rearrangement-positive cholangiocarcinoma. The product label describes it as a kinase inhibitor.

General use cases

  • Treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harbouring an FGFR2 gene fusion or other rearrangement, under the US LYRFIGTU product label (approved September 23, 2026).

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Lirafugratinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Lirafugratinib Permitted Daily Exposure (PDE) report (the Lirafugratinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Lirafugratinib Occupational Exposure Limit (OEL) report (the Lirafugratinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.